



Pfizer Limited

The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

November 26, 2020

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai - 400 001
Scrip Code: 500680

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Scrip Symbol: PFIZER

Dear Sirs,

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions, in the format specified in the accounting standards for the half year ended September 30, 2020.

The said disclosure is also available on the website of the Company i.e., www.pfizerindia.com

Please take the above on record.

Thanking you,

Yours truly,
For Pfizer Limited

Prajeet Nair
Company Secretary

Encl: A/a

CIN: L24231MH1950PLC008311

✉ contactus.india@pfizer.com

🌐 www.pfizerindia.com

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2020

Currency: ₹ in crore

Related party transactions

I. Names of related parties and description of relationships

A. Parties where control exists:

Ultimate holding company:
Pfizer Inc., USA

B. Companies collectively exercising significant influence:

Pfizer East India B.V., Netherlands
Wyeth LLC, USA
Wyeth Holdings Corporation, USA
John Wyeth & Brother Limited, UK
Warner - Lambert Company, LLC, USA
Parke - Davis & Company, LLC, USA
Pharmacia Corporation, USA
[Collectively holding 63.92% of the aggregate of equity share capital of the Company]

C. Fellow subsidiaries with whom transactions have taken place during the half year/ year end

Pfizer Products India Private Limited, India
Pfizer Innovative Supply Point International BVBA, Belgium
Pfizer Service Company BVBA, Belgium
Pfizer Worldwide Services, Ireland
Pfizer Asia Manufacturing PTE, Singapore
Pfizer Canada Inc

D. Key managerial personnel

Mr. S. Sridhar - Managing Director
Mr. Milind Patil - Wholetime Director & Chief Financial Officer
Mr. Vivek Dhariwal - Wholetime Director (upto 14 February 2020)
Mr. Samir Kazi (w.e.f 14 February 2020)
Mr. R A Shah - Independent Director
Mr. Pradip Shah - Independent Director
Mr. Uday Khanna - Independent Director
Mr. Sunil Lalbhai - Independent Director
Ms.Meena Ganesh - Independent Director

E. Relative of Key managerial personnel

Mr. Akhilesh Iyer (upto 30 June 2020)

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2020

Currency: ₹ in crore

Transactions during the half year and balances outstanding as at the half year ended September 30, 2020 with the related parties are as follows:

No.	Nature of transactions	30 September 2020				31 March 2020			
		Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Total	Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Total
1	Service income	-	-	22.89	22.89	-	-	55.19	55.19
2	Recovery of expenses	-	-	0.12	0.12	0.54	0.03	0.19	0.73
3	Purchase of stock-in-trade	-	-	180.88	180.88	-	-	393.41	393.41
4	Purchase of raw / bulk materials	-	-	10.22	10.22	-	-	115.05	115.05
5	Dividend in respect of the year ended 31 March 2020/ 2019	-	965.02	-	965.02	-	65.77	-	65.77
6	Asset transfer	-	2.12	-	2.12	-	1.42	8.59	10.01
No.	Nature of transactions	30 September 2020				31 March 2020			
		Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Total	Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	Total
8	Outstanding as at the half year / year end – Due from	-	0.09	9.52	9.61	0.54	0.09	20.99	21.62
9	Outstanding as at the half year / year end – Due to	11.05	6.46	138.43	155.94	11.18	6.47	271.20	288.85

Key managerial personnel

No.	Nature of transactions	Half Year ended 30 September	Year ended 31 March 2020
1	Remuneration to key management personnel *	5.47	9.22

* Excludes amounts payable to key management personnel towards gratuity and compensated absences.

Details of material transactions:

	Half Year ended 30 September	Year ended 31 March 2020
a) Service income		
Pfizer Products India Private Limited	10.81	25.60
Pfizer Worldwide Services	12.09	29.59
b) Recovery of expenses		
Pfizer Products India Private Limited	0.12	0.19
Pfizer Inc., USA	-	0.54
c) Purchase of stock in trade		
Pfizer Innovative Supply Point Intl BVBA, Belgium	17.25	66.07
Pfizer Service Company BVBA, Belgium	163.63	327.34
d) Purchase of raw/ bulk materials		
Pfizer Service Company BVBA, Belgium	6.79	111.62
e) Dividend paid		
Pfizer East India B.V.	600.15	40.92
Wyeth LLC, USA	185.38	12.64
g) Remuneration to key management personnel		
S. Sridhar	2.57	4.11
Milind Patil	1.61	2.10
Vivek Dhariwal (Upto 14 February 2020)	-	1.88
Samir Kazi (w.e.f 14 February 2020)	0.88	0.16

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2020

Currency: ₹ in crore

Related party transactions (Continued)

	Half Year ended 30 September 2020	As on 31 March 2020
h) Outstanding as at the half year/ year end due from		
Pfizer Worldwide Services	2.56	5.70
Pfizer Products India Private Limited, India	6.96	15.29
i) Outstanding as at the half year/ year end due to		
Pfizer Innovative Supply Point Intl BVBA, Belgium	11.51	15.81
Pfizer Service Company BVBA, Belgium	26.15	152.55
Pfizer Export Company, Ireland	82.43	82.85